| Title |
Management of Microvascular Angina Pectoris
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, October 2013
|
| DOI | 10.1007/s40256-013-0052-1 |
| Pubmed ID | |
| Authors |
Gaetano A. Lanza, Rossella Parrinello, Stefano Figliozzi |
| Abstract |
Microvascular angina (MVA) is defined as angina pectoris caused by abnormalities of small coronary arteries. In its most typical presentation, MVA is characterized by angina attacks mainly caused by effort, evidence of myocardial ischemia on non-invasive stress tests, but normal coronary arteries at angiography. Patients with stable MVA have excellent long-term prognoses, but often present with persistent and/or worsening of angina symptoms. Treatment of MVA is initially based on standard anti-ischemic drugs (beta-blockers, calcium antagonists, and nitrates), but control of symptoms is often insufficient. In these cases, several additional drugs, with different potential anti-ischemic effects, have been proposed, including ranolazine, ivabradine, angiotensin-converting enzyme (ACE) inhibitors, xanthine derivatives, nicorandil, statins, alpha-blockers and, in perimenopausal women, estrogens. In patients with 'refractory MVA', some further alternative therapies (e.g., spinal cord stimulation, pain-inhibiting substances such as imipramine, rehabilitation programs) have shown favorable results. |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 15% |
| Student > Master | 9 | 12% |
| Student > Bachelor | 9 | 12% |
| Researcher | 7 | 9% |
| Student > Ph. D. Student | 7 | 9% |
| Other | 13 | 18% |
| Unknown | 18 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 45% |
| Nursing and Health Professions | 8 | 11% |
| Sports and Recreations | 3 | 4% |
| Psychology | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 2 | 3% |
| Unknown | 24 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2023.
All research outputs
#2,760,048
of 24,736,359 outputs
Outputs from American Journal of Cardiovascular Drugs
#48
of 457 outputs
Outputs of similar age
#25,126
of 219,342 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#1
of 9 outputs
Altmetric has tracked 24,736,359 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 457 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,342 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them